Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute my…
| Métrica | HEMO.L | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -626.1% | -39.2% | -586.9% |
| ROA | -133.4% | -30.9% | -102.5% |
| Current Ratio | 0.72 | 2.73 | -2.01 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -133.4% | — |
| ✗Flujo de caja operativo positivo | −£4M | −£6M |
| ✗Rentabilidad sobre activos al alza | -133.4% | -109.6% |
| ✓Caja operativa/activos supera al ROA | -98.3% | ROA -133.4% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 0.72 | 2.93 |
| ✗Sin aumentar el nº de acciones | — | — |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | 0.00 | 0.00 |
| Calidad del negocio | FY24 |
|---|---|
| ✓ROCE > 10 % | 176.1% |
HEMOGENYX PHARMACEUTICALS PLC cotiza a 6.58 GBP y tiene una capitalización bursátil de £45M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud